Author Archives: Pharm Exec

Roche Reports Good Half-Year Performance

Roche reports a rise in sales to 22,974 million Swiss francs (+5%, US$25.5 billion) for the first half of 2014, with strong growth from HER2 breast cancer medicines, Herceptin, Perjeta and Kadcyla, and other oncology medicines, Avastin and MabThera/Rituxan. Sales of Xeloda, a chemotherapy drug which is no longer patent-protected, were lower, as a result […]
Posted in Europe, Guest Blog | Tagged , | Leave a comment

Compounding Pharmacy Issues Recall, But Challenges FDA Decision

FDA has posted on a July 19, 2014 press statement from Unique Pharmaceuticals, which reports a voluntary nationwide recall of all sterile drug preparations compounded by the outsourcing facility that have not reached the expiration date listed on the products.
Posted in FDA, Regulatory, Safety | Tagged , | Leave a comment

Pharma Rep Access Down 33 Per Cent Since 2008

The steady decline of pharmaceutical sales representative access to physicians is spreading to previously rep-friendly specialties, says the ZS Associates spring 2014 AccessMonitorT report.
Posted in E-Media, Marketing, multimedia, Sales, social media, Technology | Tagged , , | Leave a comment

Shire Takeover "Could Save AbbVie $8 Billion Tax on Humira over Next 15 Years"

AbbVie’s recent $54 billion acquisition of Shire and subsequent relocation to Ireland will mean substantial tax savings for the US pharmaceutical giant, according to analysts at research and consulting firm GlobalData.
Posted in Deals, Europe, Global, Strategy | Tagged , , , , | Leave a comment

Biotech Stocks Shaken by Fed Warning

Today’s Financial Times (FT) reports that nearly $40bn was wiped from the biotech market’s value last week (a 6 per cent drop in the Nasdaq biotechnology index) following the Federal Reserve’s identification of biotech shares as a cause for concern. There was some recovery on Friday however when prices rebounded 3 per cent. The US […]
Posted in Biotech | Tagged , , | Leave a comment
  • Categories

  • Meta